Core Viewpoint - Gannee Pharmaceutical (603087.SH) has signed a Technical Transfer and Supply Agreement with Funda o Oswaldo Cruz-Bio-Manguinhos (FZ) and BIOMM S.A. for a partnership project in Brazil, which is expected to positively impact the company's financial performance in 2025 and beyond [1] Group 1 - The company has entered into a Technical Transfer and Supply Agreement involving the transfer of insulin glargine technology and the supply of active pharmaceutical ingredients and injection solutions [1] - A Supply Framework Agreement has also been signed with BIOMM, with a total contract value expected to be no less than RMB 3 billion (including tax), subject to actual order amounts [1] - Both agreements are part of the company's routine business operations and align with its strategic development direction, potentially enhancing overall profitability [1]

Core Viewpoint - The company has signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos (FZ) and BIOMM S.A. for the Brazil Production Development Partnership (PDP) project, which is expected to positively impact its financial performance in 2025 and beyond [1] Group 1 - The company signed a technology transfer and supply agreement involving insulin glargine technology transfer and the supply of active pharmaceutical ingredients and injection solutions [1] - The supply framework agreement with BIOMM is valued at no less than 3 billion RMB (including tax), with the final amount based on actual orders [1] - The contracts are part of the company's routine operations and align with its strategic development direction, potentially enhancing overall profitability [1]

Group 1 - The company, Ganli Pharmaceutical (603087.SH), has signed a "Technology Transfer and Supply Agreement" with Fundação Oswaldo Cruz-Bio-Manguinhos (FZ) and BIOMM S.A. for a partnership project in Brazil [1] - Additionally, the company has entered into a "Supply Framework Agreement" with BIOMM, with a total contract value expected to be no less than 3 billion RMB (including tax), subject to actual order amounts [1]

甘李药业股份有限公司 关于重大合同的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，甘李药业股份有限公司（以下简称"公司"）与 Fundação Oswaldo Cruz -Bio-Manguinhos（以下简称"FZ"）以及 BIOMM S.A.（以下简称"BIOMM"） 就巴西生产开发伙伴关系计划项目（以下简称"PDP 项目"）签订了《技术转移 与供应协议》（以下简称"合同一"）。同时，公司与 BIOMM 签订了《供应框 架协议》（美元合同）（以下简称"合同二"），合同二总金额预计不低于人民 币 300,000.00 万元（含税），最终以实际订单金额为准。 上述合同系日常经营性合同，公司与交易对方均不存在关联关系，所涉及的 交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重大 资产重组。上述合同的签订在公司总经理审批权限范围内，已履行公司内部审批 程序。根据《上海证券交易所股票上市规则》和公司章程规定，上述合同无需提 交公司董事会和股东大会审议。 证券代码：603087 证券简称：甘李药业 公 ...

Core Viewpoint - The company has signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos and BIOMM, which is expected to positively impact its operating performance in 2025 and beyond [1] Group 1: Agreements and Financial Implications - The technology transfer agreement involves the transfer of insulin technology and the supply of active pharmaceutical ingredients and injectable solutions [1] - The total amount of the supply framework agreement is expected to be no less than RMB 3 billion, with the final amount based on actual orders [1] - The signing of these contracts has been approved within the company's general manager's authority and has followed internal approval procedures [1] Group 2: Future Impact - The execution of these contracts is anticipated to enhance the company's overall profitability [1] - The agreements are expected to have a positive effect on the company's operating performance in 2025 and subsequent years [1]

Core Viewpoint - The company has signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos and BIOMM, which is expected to positively impact its financial performance in 2025 and beyond [1] Group 1: Agreements - The technology transfer and supply agreement involves the transfer of insulin glargine technology and the supply of active pharmaceutical ingredients and injection solutions [1] - The total amount of the supply framework agreement is expected to be no less than RMB 3 billion, with the final amount determined by actual order values [1] - The signing of the contracts has been approved within the company's general manager's authority and has followed internal approval procedures [1] Group 2: Financial Impact - The execution of these contracts is anticipated to have a positive effect on the company's operating performance in 2025 and subsequent years [1] - The agreements are expected to enhance the overall profitability of the company [1]

Group 1 - A total of 22 companies were investigated by well-known institutions from September 15 to September 22 [1] - The automotive and electronics sectors received the most attention, followed by the biotechnology sector [1] - The company with the highest number of institutional investigations was Hanhigh Group, with 91 institutions participating, followed by World (86 institutions) and Ganli Pharmaceutical (84 institutions) [1] Group 2 - Notable investigations included companies such as Aobi Zhongguang (38 institutions), Welly Transmission (8 institutions), and Changhua Chemical (5 institutions) [2] - Other companies receiving significant attention were Chao Hong Ji (53 institutions), Sanxin Tourism (30 institutions), and Keshun Co. (30 institutions) [2] - Multiple institutions simultaneously investigated Hanhigh Group and Chao Hong Ji, indicating strong interest in these companies [2]

截至6月30日，甘李药业股东户数7.73万，较上期增加3.08%；人均流通股7165股，较上期减少2.99%。 2025年1月-6月，甘李药业实现营业收入20.67亿元，同比增长57.18%；归母净利润6.04亿元，同比增长 101.96%。 分红方面，甘李药业A股上市后累计派现16.12亿元。近三年，累计派现10.18亿元。 机构持仓方面，截止2025年6月30日，甘李药业十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股750.99万股，相比上期增加17.48万股。招商国证生物医药指数A（161726）位居第五大流 通股东，持股580.26万股，相比上期减少24.16万股。南方中证500ETF（510500）位居第六大流通股 东，持股536.87万股，相比上期增加69.27万股。创新药（159992）位居第八大流通股东，持股340.55万 股，为新进股东。南方阿尔法混合A（010357）位居第十大流通股东，持股264.69万股，为新进股东。 华安聚优精选混合（009714）退出十大流通股东之列。 责任编辑：小浪快报 9月23日，甘李药业盘中下跌2.01%，截至10:09，报72.12元/股，成 ...

Core Insights - In the past five trading days, a total of 281 companies were investigated by institutions, with notable interest in companies like Ganfeng Lithium, Hanhai Group, and Dingtong Technology [1][2] Group 1: Institutional Research Activity - 83.27% of the companies investigated had participation from securities firms, with 234 companies being surveyed [1] - Fund companies conducted research on 191 companies, while private equity firms investigated 82 companies [1] - Ganfeng Lithium received the highest attention with 91 institutions participating in its research, followed by Hanhai Group also with 91 institutions [1][2] Group 2: Fund Flow and Stock Performance - Among the stocks investigated by more than 20 institutions, 11 experienced net inflows in the past five days, with Guorui Technology seeing the highest net inflow of 284 million yuan [1] - Hanhai Group and Lais Information also had significant net inflows of 79 million yuan and 70 million yuan respectively [1] - In terms of stock performance, 31 stocks increased in value, with Demingli, Shuanghuan Transmission, and Guangdong Hongda leading with gains of 31.55%, 24.06%, and 21.07% respectively [2] Group 3: Detailed Company Insights - Ganfeng Lithium (603087) was investigated once by 91 institutions, with a closing price of 73.60 yuan and a slight decline of 0.35% [2] - Hanhai Group (001221) also had 91 institutions participating, closing at 67.41 yuan with a notable increase of 17.64% [2] - Dingtong Technology (688668) was investigated by 77 institutions, closing at 108.94 yuan with a gain of 3.26% [2]

证券之星消息，9月22日，医疗健康R（480016）指数报收于8194.9点，涨0.05%，成交322.04亿元，换手 率1.01%。当日该指数成份股中，上涨的有18家，甘李药业以3.76%的涨幅领涨，下跌的有32家，普洛药 业以3.21%的跌幅领跌。 资金流向方面，医疗健康R（480016）指数成份股当日主力资金净流出合计5.59亿元，游资资金净流出合 计2332.11万元，散户资金净流入合计5.83亿元。成份股资金流向详情见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603259 | 药明康德 | 2.78亿 | 5.82% | 1890.96万 | 0.40% | -2.97 Z | -6.21% | | 300760 迈瑞医疗 | | 7942.85万 | 4.41% | -1.25 Z | -6.97% | 4606.51万 | 2.56% | | 600276 恒瑞医药 | | 6401.37 ...